Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm
NCT07284511
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar (TZP)
Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial
Sponsor: Breakthrough T1D
Interventions
Carbohydrate Counting No Meal Announcement Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) Tirzepatide
Updated 1 time since 2026 Last updated: Dec 8, 2025 Started: Jan 5, 2026 Primary completion: Jan 31, 2028 Completion: Jan 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2/PHASE3 clinical study on T1D and T1DM, this trial is actively recruiting participants. The trial is conducted by Breakthrough T1D and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Breakthrough T1D
- Insel Gruppe AG, University Hospital Bern
- Institut de Recherches Cliniques de Montreal
- Melissa-Rosina Pasqua
Data source: McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .